Synklino Revenue and Competitors
Estimated Revenue & Valuation
- Synklino's estimated annual revenue is currently $5.1M per year.
- Synklino's estimated revenue per employee is $155,000
Employee Data
- Synklino has 33 Employees.
- Synklino grew their employee count by 6% last year.
Synklino's People
| Name | Title | Email/Phone |
|---|
Synklino Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Synklino?
Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.
keywords:N/A
N/A
Total Funding
33
Number of Employees
$5.1M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Copenhagen N
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.3M | 36 | 29% | N/A |
#2 | $38.5M | 154 | -15% | N/A |
#3 | N/A | 187 | 33% | N/A |